TruAlt Bioenergy Reports Lower FY26 Standalone Revenue Amid Diversification Push

TruAlt Bioenergy Limited announced its audited financial results for the fiscal year ended March 31, 2026. The company's standalone revenue for FY26 stood at ₹1,704 crore, a decrease from ₹1,880 crore in FY25. Standalone Profit After Tax (PAT) also saw a decline, falling to ₹80.26 crore from ₹140.00 crore in the previous year.

Reader Takeaway: Revenue hit by policy; diversification into CBG, SAF, and retail aims to stabilize earnings.

What just happened

TruAlt Bioenergy reported a dip in its standalone revenue and profit for the fiscal year 2025-26. Standalone revenue decreased by approximately 9% to ₹1,704 crore from ₹1,880 crore in the prior year. The standalone PAT fell significantly to ₹80.26 crore from ₹140.00 crore.

This performance was attributed to challenges in tender allocation methodologies for ethanol and the pending implementation of court-ordered volumes. However, the company's consolidated PAT for FY26 was ₹96.86 crore.

Why this matters

The financial results highlight the company's vulnerability to external policy and regulatory factors affecting its core ethanol business. The decline in profitability signals pressure from increased finance costs and depreciation, likely due to significant capital expenditure on new projects. The diversification strategy into Compressed Biogas (CBG), Sustainable Aviation Fuel (SAF), and fuel retail is crucial for future growth and de-risking the business model.

The backstory

In the previous fiscal year (FY25), TruAlt Bioenergy had reported higher standalone revenue of ₹1,880 crore and PAT of ₹140.00 crore. The company's operational performance has been closely watched by investors, given the evolving landscape of biofuels in India. The current results reflect ongoing adjustments to policy frameworks and the company's efforts to adapt.

What changes now

TruAlt Bioenergy is actively transitioning into a diversified biofuels platform. The company's strategic focus is now on expanding its presence in CBG, SAF, and fuel retail. The subsidiary, Leafiniti Bioenergy, which handles the CBG vertical, showed growth with revenue increasing to ₹42.84 crore in FY26 from ₹28.42 crore in FY25.

The management confirmed achieving 24 crore litres of ethanol volumes against tenders, with a pending implementation of 15 crore litres of court-ordered volumes, which could impact short-term revenue realization.

Risks to watch

The primary risk remains the company's dependence on Oil Marketing Company (OMC) tender allocations and policy stability within the biofuel sector. Pending court-ordered volumes create uncertainty. Additionally, high capitalization for new plants is leading to increased finance and depreciation costs, impacting the bottom line.

Peer comparison

While specific peer financial data for FY26 is not immediately available in the filing, the biofuel sector in India is characterized by evolving government policies and increasing competition. Companies in this space often face similar challenges related to feedstock availability, price volatility, and regulatory approvals. TruAlt's diversification strategy aims to create a more resilient business model compared to peers solely focused on ethanol.

Context metrics (time-bound)

• Standalone Revenue FY26: ₹1,704 crore (vs ₹1,880 crore in FY25)
• Standalone PAT FY26: ₹80.26 crore (vs ₹140.00 crore in FY25)
• Consolidated PAT FY26: ₹96.86 crore
• Leafiniti Bioenergy Revenue FY26: ₹42.84 crore (vs ₹28.42 crore in FY25)
• Standalone EBITDA Margin FY26: 19.81% (vs 18.98% in FY25)

What to track next

Investors will be keen to observe the successful implementation of court-ordered ethanol volumes and the progress in scaling up CBG, SAF, and retail fuel operations. Monitoring policy updates related to biofuels and the company's ability to manage its debt and depreciation costs will be critical.